Home LiteratureArticle Details
PMID: 9218672 Published · ppublish English Journal Article Multicenter Study

Epidemiology of sepsis syndrome in 8 academic medical centers.

JAMA ·Vol. 278 ·No. 3 ·1997-07-16 ·Pages 234-40

Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL, Platt R, Academic Medical Center Consortium Sepsis Project Working Group

Abstract

Sepsis syndrome is a leading cause of mortality in hospitalized patients. However, few studies have described the epidemiology of sepsis syndrome in a hospitalwide population. To describe the epidemiology of sepsis syndrome in the tertiary care hospital setting. Prospective, multi-institutional, observational study including 5-month follow-up. Eight academic tertiary care centers. Each center monitored a weighted random sample of intensive care unit (ICU) patients, non-ICU patients who had blood cultures drawn, and all patients who received a novel therapeutic agent or who died in an emergency department or ICU. Sepsis syndrome was defined as the presence of either a positive blood culture or the combination of fever, tachypnea, tachycardia, clinically suspected infection, and any 1 of 7 confirmatory criteria. Estimates of total cases expected annually were extrapolated from the number of cases, the period of observation, and the sampling fraction. From January 4, 1993, to April 2, 1994, 12759 patients were monitored and 1342 episodes of sepsis syndrome were documented. The extrapolated, weighted estimate of hospitalwide incidence (mean+/-95% confidence limit) of sepsis syndrome was 2.0+/-0.16 cases per 100 admissions, or 2.8+/-0.17 per 1000 patient-days. The unadjusted attack rate for sepsis syndrome between individual centers differed by as much as 3-fold, but after adjustment for institutional differences in organ transplant populations, variation from the expected number of cases was reduced to 2-fold and was not statistically significant overall. Patients in ICUs accounted for 59% of total extrapolated cases, non-ICU patients with positive blood cultures for 11%, and non-ICU patients with negative blood cultures for 30%. Septic shock was present at onset of sepsis syndrome in 25% of patients. Bloodstream infection was documented in 28%, with gram-positive organisms being the most frequent isolates. Mortality was 34% at 28 days and 45% at 5 months. Sepsis syndrome is common in academic hospitals, although the overall rates vary considerably with the patient population. A substantial fraction of cases occur outside ICUs. An understanding of the hospitalwide epidemiology of sepsis syndrome is vital for rational planning and treatment of hospitalized patients with sepsis syndrome, especially as new and expensive therapeutic agents become available.

MeSH Terms
Adult Aged Cross Infection/epidemiology Data Collection Diagnosis-Related Groups Female Hospitals, Teaching/statistics & numerical data Humans Incidence Intensive Care Units Male Middle Aged Prospective Studies Statistics as Topic Systemic Inflammatory Response Syndrome/epidemiology,physiopathology
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Sands K E
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA. ksands@bidmc.harvard.edu
Bates D W
Lanken P N
Graman P S
Hibberd P L
Kahn K L
Parsonnet J
Panzer R
Orav E J
Snydman D R
Black E
Schwartz J S
Moore R
Johnson B L
Platt R
Academic Medical Center Consortium Sepsis Project Working Group
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
0098-7484
Published
1997-07-16
Pages
234-40
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com